4/5-Cognitive Neuroscience Task Reliability & Clinical Applications Consortium

4/5-认知神经科学任务可靠性

• 批准号: 7847800
• 负责人: James M. Gold
• 金额: $ 29.81万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7847800
• 关键词: Activities of Daily Living; Address; Adverse effects; Aging; Area; Awareness; Basic Science; Behavioral; Behavioral Paradigm; Biocompatible Materials; Bioinformatics; Biological; Biological Markers; Brain; Brain imaging; Characteristics; Clinical; Clinical Investigator; Clinical Trials; Clinical assessments; Cognition; Cognitive; Cognitive deficits; Collaborations; Computer Systems; Consensus; Data; Data Analyses; Data Storage and Retrieval; Development; Ensure; Equipment; Evaluation; Explosion; Floor; Functional Imaging; Functional Magnetic Resonance Imaging; Funding; Genetic Polymorphism; Goals; Healthcare; Hour; Human; Image; Image Analysis; Impaired cognition; Individual; Individual Differences; Intervention; Knowledge; Lead; Length; Letters; Life; Linear Models; Literature; Maintenance; Measurement; Measures; Mediator of activation protein; Mental disorders; Methods; Modeling; Modification; Multi-Institutional Clinical Trial; National Institute of Mental Health; Neurosciences Research; Occupations; Outcome; Parents; Patients; Pattern; Perception; Performance; Persons; Pharmaceutical Preparations; Positioning Attribute; Principal Component Analysis; Process; Property; Psychometrics; Recording of previous events; Recruitment Activity; Research; Research Infrastructure; Retrieval; Sampling; Schizophrenia; Series; Signal Transduction; Site; Standardization; Stimulus; System; Task Performances; Testing; Time; Training; Translating; Translation Process; Translations; Universities; Validation; Visual; Washington; Work; base; clinical application; cognitive function; cognitive neuroscience; college; design; drug development; effective therapy; experience; functional outcomes; imaging modality; improved; independent component analysis; indexing; interest; meetings; member; neuroimaging; process optimization; public health relevance; relating to nervous system; response; skills; success; symposium; theories; therapy design; treatment effect; treatment response; visual control

DESCRIPTION (provided by applicant): This is a competitive revision in response to NOT-OD-09-058, the ARRA call for Competitive Supplement Applications. In the past decade there has been a growing awareness of the disabling effects of impaired cognition in individuals with schizophrenia and the importance of developing new treatments that target cognitive deficits. During this same period, the cognitive neuroscience field has seen an explosion of new knowledge regarding the neural basis of cognition. The application of this new knowledge to drug development in schizophrenia has lagged significantly behind overall progress in cognitive neuroscience, in large part due to the lack of data on the measurement properties of tasks used in cognitive neuroscience. This concern led to the Cognitive Neuroscience Research To Improve Cognition in Schizophrenia (CNTRICS) initiative, which conducted a series of conferences designed to develop consensus on the constructs and paradigms from cognitive neuroscience that are ripe for translation for use in clinical trials contexts. We were recently funded to start this translation process (Cognitive Neuroscience Task Reliability & Clinical Applications (CNTRACs) Consortium.") for behavioral paradigms. We brought together a collaborative team that represents significant expertise from the many fields necessary for the success of this endeavor. We are focusing on four constructs that span both early (gain control and visual integration in perception) and higher-level (goal maintenance, relational encoding and retrieval) components of human cognitive processing. Is this competitive revision we will extend this work in a highly critical and significant direction that the field has identified as a growing need - the development of well validated, and reliable functional neuroimaging paradigms that can serve as biomarkers for predicting and assessing drug and intervention response to treatments designed to enhance cognition. This focus meets one of the key topic areas for Competitive Supplements identified by the NIMH, namely Biomaterials and Biological Measures for the Study of Mental Disorders, which includes "Systematically collecting and analyzing biological measures (e.g., genetic polymorphisms, brain imaging indexes), which could be used, also in combination with clinically derived variables, to identify predictors of outcome, moderators of treatment response and adverse effects, or mediators and patterns of treatment effects." The end goal for these expanded aims will be to provide the field with: 1) easy to use imaging paradigms of these three cognitive functions that: 2) have been optimized for use in a clinical trials context (efficient, reliable, robust); while 3) maintaining their validity as specific measures of the cognitive and neural processes of interest. We believe that it is feasible to complete this added Aim in the time frame of the ARRA announcement, given that we have an established infrastructure. This set of collaborative R01 proposals meet the goals of the ARRA stimulus by providing for funding for 9 new positions, 3 positions that would allow us to retain staff that would otherwise need to be let go, and 1 position that we can increase from part to full time. PUBLIC HEALTH RELEVANCE: This project has high relevance for public health by significantly improving our ability to translate paradigms developed into the basic cognitive neuroscience literature for use in clinical trials aimed at improving cognition in schizophrenia. Cognitive deficits in schizophrenia are a major predictor of functional outcome in this debilitating illness. Thus, we need to improve our methods for detecting and enhancing cognitive function in schizophrenia in order to help individuals with this illness lead more productive and fulfilling lives.

描述（由申请人提供）：这是对NOT-OD-09-058的竞争性修订版，这是竞争性补充申请的ARRA呼吁。在过去的十年中，人们对精神分裂症患者认知受损的残疾影响以及开发针对认知缺陷的新疗法的重要性越来越认识。在同一时期，认知神经科学领域已经看到了有关认知神经基础的新知识的爆炸。这种新知识在精神分裂症的药物开发中的应用显着落后于认知神经科学的总体进步，这在很大程度上是由于缺乏有关认知神经科学中任务的测量特性的数据。这一关注导致了认知神经科学研究，以改善精神分裂症（CNTRICS）倡议的认知，该计划进行了一系列会议，旨在在认知神经科学的构建体和范式上建立共识，这些会议是成熟的，可以在临床试验环境中转化。最近，我们资助了这一翻译过程（认知神经科学任务可靠性和临床应用（CNTRACS）财团。检索人类认知处理的组成部分。在精神疾病研究中，包括生物材料和生物学措施，包括“系统地收集和分析生物学措施（例如，遗传多态性，脑成像索引），也可以使用临床派生的变量，以识别治疗响应的预测因素，或者对临床的预测因素，以识别临床上的效果和差异效果。将提供以下领域：1）易于使用这三种认知功能的成像范式：2）已在临床试验环境（高效，可靠，稳健）中进行了优化供使用； 3）保持其有效性作为感兴趣的认知和神经过程的特定措施。我们认为，在ARRA公告的时间范围内完成此额外的目标是可行的，因为我们已经建立了基础架构。这套协作R01提案通过为9个新职位提供资金，3个职位，这使我们能够保留本来需要放手的员工，以及我们可以从一部分到全职可以提高的1个职位，从而实现了ARRA刺激的目标。 公共卫生相关性：该项目与公共卫生具有很高的相关性，它可以显着提高我们将发展范式转化为基本认知神经科学文献的能力，用于用于改善精神分裂症认知的临床试验。精神分裂症的认知缺陷是这种使人衰弱的疾病中功能结果的主要预测指标。因此，我们需要改善我们在精神分裂症中检测和增强认知功能的方法，以帮助患有这种疾病的人带来更具富有成效和充实的生活。